While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

After all the Tuberculosis outbreaks in Kansas, both the Lubbock Health Department and Covenant Medical Center explained what ...

Choose from Muscular Dystrophy stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials ...

Choose from Muscular Dystrophy Treatment stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

Laboratory tests can monitor for renal toxicity and coagulation abnormalities, including acute severe low platelet counts, which have been observed after administration of some ASOs. Biogen licensed ...

Not all heroes wear capes – and it couldn’t be more true for these everyday champions from Regional New South Wales who have ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Personalized organoids — ‘mini-organs’ — may accelerate treatment for patients with rare genetic disorders. Courtesy of Europeana via Unsplash Across the globe, countless babies ...